Program
foslinanib
Also written as “CVM-1118”, “CVM-1118 + Sintilimab + TACE” and “CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)”.
Its studies are mostly in Carcinoma, Hepatocellular · Neuroendocrine Tumors · Neoplasms, led by TaiRx.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TaiRx | 53 open or running | phase 2since May 21, 2018 | May 21, 2018 | Dec 31, 2026phase 2 · NCT05257590 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 21, 2018First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT03582618 · 12 enrolled · United States, Taiwan
- Jun 7, 2018Phase 2 study in Neuroendocrine TumorsNCT03600233 · 34 enrolled · Taiwan
- Mar 31, 2020Phase 1 study in NeoplasmsNCT04336124 · 5 enrolled · Taiwan
- Feb 8, 2022Phase 2 study in Carcinoma, HepatocellularNCT05257590 · 95 planned · Taiwan
- Mar 31, 2026Phase 2 study in Carcinoma, HepatocellularNCT07521852 · 40 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularNCT05257590
- Dec 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07521852
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07521852Carcinoma, Hepatocellular · China | 2 | Recruiting | Dec 31, 2027 | 40 |
| NCT05257590Carcinoma, Hepatocellular · Taiwan | 2 | Recruiting | Dec 31, 2026 | 95 |
| NCT04336124Neoplasms · Taiwan | 1 | Completed | Feb 8, 2021 | 5 |
| NCT03600233Neuroendocrine Tumors · Taiwan | 2 | Active, not recruiting | Sep 30, 2024 | 34 |
| NCT03582618Carcinoma, Hepatocellular · United States, Taiwan | 2 | Terminated | Nov 16, 2021 | 12 |
How it is read
Names in the registry
- “CVM-1118”, 3 entries
- “CVM-1118 + Sintilimab + TACE”, 1 entry
- “CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 3 studies
- Neuroendocrine Tumors, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.